Active specific immunotherapy with tumor cells and Corynebacterium parvum: a phase I study.
Autologous, irradiated (10,000 rads) tumor cells mixed with C. parvum were given as weekly intracutaneous injections to fifteen patients with residual malignant disease. The toxicity was minimal and distinctly less than has been seen with tumor cell-BCG immunotherapy. A goal of 4 injections of 10(7) cells each was possible in only 4 patients because of limitations in methods of disaggregation and quantity of tumor available. The feasibility aspects are discussed and a case report of a prolonged regression is presented.
D000230:Adenocarcinoma / Q000628:therapy; D000368:Aged; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003352:Corynebacterium / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007271:Injections, Intradermal; D007680:Kidney Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013997:Time Factors
D000951:Antigens, Neoplasm; D001428:Bacterial Vaccines